作者：
Himmel, H. M. [1]
;
Delaunois, A. [2]
;
Deurinck, M. [3]
;
Dinklo, T. [4]
;
Faelker, Eriksson T. M. [5]
;
Habermann, C. [6]
;
Heers, C. [7]
;
Hempel, K. [8]
;
Lorenz, H. [9]
;
Rosch, A. [10]
;
Schauerte, H. ;
Teuns, G. ;
Traebert, M. ;
van Amsterdam, C. ;
van der Linde, H.
作者单位：
UCB Biopharma SPRL, Chemin Foriest, B-1420 Braine Lalleud, Belgium
[1]
Novartis Pharma AG, Novartis Inst Biomed Res, CH-4002 Basel, Switzerland
[2]
Merck, Global Non Clin Safety, Frankfurter Str 250, D-64293 Darmstadt, Germany
[3]
Janssen, Janssen Pharmaceut NV, Global Safety Pharmacol, Turnhoutseweg 30, B-2340 Beerse, Belgium
[4]
Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Basel, Switzerland
[5]
Boehringer Ingelheim Pharma GmbH & Co KG, Birkendorfer Str 65, D-88397 Biberach, Germany
[6]
AbbVie Deutschland GmbH & Co KG, Dept Preclin Safety, Knollstr, D-67061 Ludwigshafen, Germany
[7]
Grunenthal GmbH, Grunenthal Innovat, D-52078 Aachen, Germany
[8]
Merz Pharmaceut GmbH, Alfred Wegener Str 2, D-60438 Frankfurt, Germany
[9]
Bayer AG, Safety Pharmacol, Aprather Weg 18a, D-42096 Wuppertal, Germany
[10]
发布时间
2020-11-27
换一批
换一批
